Recombinant Human PD-L1/B7-H1/CD274 Protein (mFc Tag)

Recombinant Human PD-L1/B7-H1/CD274 Protein (mFc Tag)

SKU #	PKSH032871
Expression Host	HEK293 Cells

Description

Synonyms	B7 Homolog 1,B7-H1,B7H1,CD274,PD-L1,PDCD1 Ligand 1,PDCD1L1,PDCD1LG1,PDL1,Programmed Cell Death 1 Ligand 1,Programmed Death Ligand 1
Species	Human
Expression Host	HEK293 Cells
Sequence	Phe19-Thr 239
Accession	Q9NZQ7
Calculated Molecular Weight	50.9 kDa
Observed Molecular Weight	59-89 kDa
Tag	C-mFc
Bio-activity	Not validated for activity

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per g of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80. Reconstituted protein solution can be stored at 4-8 for 2-7 days. Aliquots of reconstituted samples are stable at < -20 for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from a 0.2 m filtered solution of PBS, pH 7.4. Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Background
CD274; also known as B7-H1 or programmed death ligand 1 (PD-L1); is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.